Leap Therapeutics, Inc. Stock
Leap Therapeutics, Inc. Stock price
Key metrics
| Market capitalization | $107.52m |
| Enterprise Value | $29.52m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.63 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-65.73m |
| Free Cash Flow (TTM) Free Cash Flow | $-50.06m |
| Cash position | $78.48m |
Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Leap Therapeutics, Inc. Stock Analysis
Analyst Opinions
5 Analysts have issued a Leap Therapeutics, Inc. forecast:
Analyst Opinions
5 Analysts have issued a Leap Therapeutics, Inc. forecast:
Financial data from Leap Therapeutics, Inc.
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.22 -0.22 |
46%
46%
|
|
| EBITDA | -66 -66 |
24%
24%
|
EBIT (Operating Income) EBIT | -66 -66 |
24%
24%
|
| Net Profit | -60 -60 |
27%
27%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Leap Therapeutics, Inc. Stock News
Company Profile
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Doug Onsi |
| Employees | 54 |
| Founded | 2011 |
| Website | www.leaptx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
